ArticleCommunications biology2025
NDRG2 upregulation induces astrocytic apoptosis via AKT inhibition and FoxO3a-Puma activation in depression.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- FGF13 alleviates astrocytic apoptosis via JIP2 inhibition in the hippocampus and mitigates depression-like behavior.Journal of neuroinflammation · 2026Article
- Hydroxytyrosol confers resilience against the depressive, anxiogenic and cognition-disruptive effects of chronic stress.Neurobiology of stress · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The loss of astrocytes represents a key pathological hallmark of major depressive disorder, yet its mechanisms remain elusive. Here, we identified NDRG2 as a critical regulator of astrocyte apoptosis in depression. NDRG2 expression is upregulated in depression models, concomitant with astrocyte loss. Overexpression of NDRG2 in astrocytes triggered apoptosis and depressive-like behaviors, with inhibition of AKT and activation of FoxO3a-Puma apoptotic signaling pathway. Mechanistically, NDRG2 recruits PP2A to AKT, facilitating its dephosphorylation and subsequent inactivation, then promotes the nuclear translocation of FoxO3a, leading to the transcriptional activation of the pro-apoptotic factor Puma. Crucially, NDRG2 knockdown in astrocytes effectively prevented astrocytic apoptosis, with effective rescue of depressive-like phenotypes. These findings reveal a key mechanism of astrocyte death in depression, wherein NDRG2 functions as an adaptor to promote PP2A-mediated AKT dephosphorylation, thereby initiating the pro-apoptotic signaling pathway, and disclose a druggable pathway for developing antidepressants targeting astrocyte preservation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.